- All > Medicine Information and Evidence for Policy > Medicines Policy
- All > Quality and Safety: Medicines > Counterfeit Medicines
- All > Quality and Safety: Medicines > Quality Assurance
- All > Quality and Safety: Medicines > Regulatory Support
(2003; 4 pages) [French] [Spanish]
The FIP is seriously concerned about the continuing, even increasing, risk to public health represented by counterfeiting of medicines, particularly in countries where legislation governing the manufacture and distribution of medicines, or the enforcement of legislation, is ineffective. The massive circulation of poor quality, harmful and counterfeit active ingredients and finished products in international commerce can seriously reduce the quality of patient care.